関連文献

Urinary liver-type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone-induced acute kidney injury.

Nephrology (Carlton). 2023doi: 10.1111/nep.14254.PubMed

Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments.

J Am Heart Assoc. 2023PubMed

Association of urinary liver-type fatty acid-binding protein with renal functions and antihyperglycemic drug use in type 2 diabetic nephropathy patients.

Int Urol Nephrol. 2023PubMed

Tubular Injury Causing Protracted Glycosuria Following Withdrawal of a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor: A Possible Role in the Development of Protracted Hypoglycemia and Ketoacidosis.

Tohoku J Exp Med. 2021PubMed

Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial.

J Diabetes Res. 2021doi: 10.1155/2021/7382620. PubMed

Effect of linagliptin on oxidative stress markers in patients with type 2 diabetes: a pilot study.

Diabetol Int. 2018PubMed

Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice.

Naunyn Schmiedebergs Arch Pharmacol. 2018PubMed

Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucoselowering-independent manner.

BMJ Open Diabetes Res Care. 2017PubMed

Role of bardoxolone methyl, a nuclear factor erythroid 2-related factor 2 activator, in aldosterone- and salt-induced renal injury.

Hypertens Res. 2017PubMed

Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensin II type 1a receptor expression.

Eur J Pharmacol. 2017PubMed